WRN and cancer: These findings suggest that WRN helicase may function as a guardian of the genome in cancer cells in which certain DNA repair pathways are vulnerable [71], and that WRN helicase inhibitors, such as PARP inhibitors, which act to increase genomic instability, may play an important role in the clinical development of cancer drugs [72].